My reasoning for taking between 1 and 2 grams per night is to reduce mitochondrial DNA damage (that is the damage to the DNA stored in the mitochondria).
I’ve taken up to 4000mg in a day. I started this mega dose after looking at studies on how powerful it is. I usually take it in 4 doses between 3pm and bed time. It does not make me sleepy. I do sleep better than I ever have, though I take it for what it does to almost all of my body systems. I’m 62 and have been a biohacker since 2015. I look great, have lots of beautiful muscles and love everything about my life … to include keeping my very young husband on his toes.
4 Likes
I take it during the night. I get to sleep ordinarily and then when I wake I start taking it. I thought I would provide a photo which I will attach to this post.
1 Like
I follow the work of Doris Loh here is a link to her
I. Executive Summary
Dr. Doris Loh’s presentation addresses a biophysical framework that repositions melatonin from a simple circadian signaling molecule to a master therapeutic coordinator of macromolecular condensation and mitochondrial integrity. The core thesis argues that liquid-liquid phase separation (LLPS), the fundamental thermodynamic process responsible for organizing membraneless organelles (MLOs), becomes pathological during aging and disease states. When these dynamic biomolecular condensates lose their fluid state, they transition into irreversible gels and toxic solid aggregates, forming the amyloid fibrillation (such as tau, alpha-synuclein, and TDP-43) characteristic of Alzheimer’s disease and other dementias. Loh posits that melatonin, operating within an evolutionary triad alongside light and water, directly regulates this phase behavior by lowering water viscosity and stabilizing protein hydration shells, preventing the entropic changes that drive protein compaction.
Furthermore, the presentation links this biophysical control to mitochondrial bioenergetics. Under conditions of age-related oxidative stress, electron transport chain leakage generates excessive reactive oxygen and nitrogen species, causing cardiolipin peroxidation and a collapse in Cytochrome c Oxidase (COX) activity. Melatonin, actively imported into the matrix via PEPT1 and PEPT2 transporters, neutralizes this cascade through its unique antioxidant degradation pathway. Loh provides preclinical evidence demonstrating that melatonin counteracts severe mitochondrial viscosity increases and direct COX inhibition induced by classic inhibitors like cyanide and ruthenium red. Additionally, she outlines a mechanism where melatonin synergizes with adenosine triphosphate (ATP), binding to its adenosine moiety to enhance ATP’s native hydrotropic capacity to dissolve pathological protein gels.
From a critical peer-review perspective, while the preclinical and in vitro evidence concerning melatonin’s mitochondrial protection is deeply established, the translation of these molecular mechanics into an overarching clinical protocol represents a massive speculative leap. No human clinical trials or meta-analyses currently show that oral administration of melatonin directly shifts phase-separated networks or stabilizes protein hydration boundaries in vivo. The clinical utility of these findings remains limited by a translational gap, and multi-gram dosing frameworks are burdened by unquantified safety risks, such as receptor desensitization and potential cardiovascular signals highlighted in modern cohort reviews. Thus, while the underlying biochemistry is compelling, the therapeutic framework remains preclinically constrained.
II. Insight Bullets
- Liquid-liquid phase separation (LLPS) represents a highly conserved, fundamental thermodynamic process utilized by living systems since prebiotic evolution to rapidly manage cellular partitioning.
- Membraneless organelles (MLOs) like stress granules, nucleoli, and nuclear bodies assemble rapidly via LLPS to isolate specific biochemical reactions without lipid boundaries.
- Eukaryotic complexity requires a high density of intrinsically disordered regions (IDRs) within corporate proteins to manage flexible, multivalent signaling interactions.
- Aberrant phase transitions cause dynamic, fluid liquid droplets to undergo phase compaction into highly viscous gels and solid, irreversible aggregates.
- In neurodegenerative landscapes, pathological phase separation underlies the amyloid fibrillation of tau, alpha-synuclein, TDP-43, and FUS.
- Phase-separated oncogenic condensates act as biophysical sanctuaries that stabilize transcriptional survival programs and protect cancer cells from pharmaceutical degradation.
- Water molecule expulsion from protein hydration shells into bulk solvent provides the negative free energy change and entropic drive that facilitates aberrant phase separation.
- High viscosity in interfacial waters surrounding biomolecular condensates destabilizes fluid phases and accelerates solid macromolecular crystallization.
- Light, water, and melatonin constitute an ancient, synergistic tri-axis engineered to maintain adequate protein hydration barriers and prevent toxic aggregation.
- Melatonin possesses a unique molecular geometry featuring five separate hydrogen-bonding coordination sites, allowing it to modify water network dynamics.
- In bulk water configurations, the carbonyl oxygen group of melatonin forms strong, stable hydrogen bonds that alter local solvent viscosity landscapes.
- Melatonin acts to lower the viscosity of interfacial and bulk water, freeing water molecules to expand and reinforce protein hydration shells.
- Elevated free water availability prevents the entropic drive toward protein compaction, keeping biomolecular condensates in a fluid, functional state.
- Adenosine triphosphate (ATP) acts at millimolar concentrations as a biological hydrotrope to prevent the aggregation of intrinsically disordered proteins independent of energy transfer.
- At lower physiological ranges, ATP stimulates the nucleation of MLOs, while at higher macro-concentrations, it acts to dissolve phase-separated droplets.
- Melatonin physically associates with ATP, binding selectively near or with the adenosine moiety of the nucleotide.
- The binding interaction between melatonin and ATP reinforces the hydrotropic capacity of the adenosine moiety, protecting against water removal from protein surfaces.
- Mitochondria function as the primary cellular factories for both ATP synthesis and baseline melatonin production within peripheral somatic tissues.
- Aging triggers a structural degradation of mitochondrial networks, shifting the electron transport chain (ETC) toward severe electron leakage.
- Chronic electron leakage drives the elevated generation of intramitochondrial reactive oxygen species (ROS) and reactive nitrogen species (RNS).
- Excessive mitochondrial ROS/RNS induces lipid peroxidation of cardiolipin within the inner mitochondrial membrane, dismantling respiratory supercomplexes.
- Melatonin is actively localized to the mitochondrial matrix via active transport driven by the PEPT1 and PEPT2 oligopeptide transporter systems.
- In the matrix, melatonin acts as a multifunctional Type I-IV free radical scavenger that breaks down into a continuous cascade of active antioxidant metabolites.
- Melatonin’s antioxidant metabolite cascade includes cyclic 3-hydroxymelatonin, AFMK, and AMK, each capable of neutralizing subsequent free radicals.
- Mitochondrial viscosity fluctuates dramatically in response to environmental toxins, oxidative stressors, and structural damage, directly indicating organelle health.
- Cyanide acts as a potent mammalian cytotoxic agent that explicitly binds and blocks Cytochrome c Oxidase (COX / Complex IV) of the electron transport chain.
- In vitro assays using rat brain mitochondria confirm that 5 micromolar potassium cyanide induces a 50% inhibition of baseline COX activity.
- Co-administration of 100 micromolar melatonin nearly completely counteracts cyanide-induced COX inhibition in a strict dose-dependent manner.
- At extreme 100 micromolar cyanide exposures, even 5 millimolar concentrations of melatonin fail to reverse a 100% inactivation of Complex IV.
- In vivo intraperitoneal administration of melatonin at 10 mg/kg in rat models significantly upregulates time-dependent COX activity across brain and liver tissues.
- Melatonin administration completely reverses the mitochondrial membrane potential collapse and oxidative stress induced by ruthenium red.
- Ruthenium complexes trigger apoptotic cascades by drastically increasing local mitochondrial viscosity and generating excessive ROS.
- Melatonin dampens lines of tension across cell membranes, actively preserving the negative curvature and fluidity of lipid bilayers.
- The structural stabilization of lipid raft domains by melatonin prevents the aberrant nucleation of pathological protein condensates at the cell boundary.
- Post-translational modifications (PTMs) dynamically govern the charge profiles of IDPs, determining whether a condensate stays liquid or shifts to a solid gel.
- Melatonin influences the balance of mRNA- and RNA-binding protein composition by regulating N6-methyladenosine (m6A) epitranscriptomic modifications.
- A distinct clinical deficit in modern pharmacology is the absolute absence of approved therapeutics designed to target aberrant phase separation.
- Melatonin’s localized actions within mitochondria prevent the induction of the pro-inflammatory NLRP3 inflammasome caused by membrane depolarization.
- The evolutionary discovery of the SNAT gene in ancient archaea confirms that melatonin’s protective relationship with biomolecular condensates predates advanced eukaryotes.
- Recalibrating allometric interspecies dosing is mandatory to bridge the massive translational gap between rodent metabolic kinetics and human clinical trials.
III. Adversarial Claims & Evidence Table
| Claim from Video | Speaker’s Evidence | Scientific Reality (Current Data) | Evidence Grade | Verdict |
|---|---|---|---|---|
| Melatonin regulates liquid-liquid phase separation (LLPS) to prevent toxic amyloid fibrillation in dementia. | Theoretical models and biophysical hypotheses co-authored with Russell J. Reiter. | Mechanism is entirely restricted to in vitro simulations and computational biophysical modeling. No human in vivo trials exist confirming that oral melatonin alters biomolecular condensates. Loh & Reiter, 2023 | Level D (Translational Gap) | Speculative |
| Melatonin physically complexes with ATP to reinforce its hydrotropic effect and prevent protein aggregation. | Molecular docking data and biochemical commentaries. | While ATP is clinically proven to act as a hydrotrope at millimolar concentrations, the direct physical synergy where melatonin binds the adenosine moiety to enhance this in human tissue remains unverified in vivo. Loh & Reiter, 2021 | Level D (Translational Gap) | Speculative |
| Melatonin counteracts 50% of Cytochrome c Oxidase (COX) inhibition induced by cyanide and reverses ruthenium red toxicity. | In vitro rat brain mitochondria assays and in vivo rodent intraperitoneal (IP) tracking models. | Preclinical data strongly support melatonin’s role in protecting Complex IV and reversing mitochondrial membrane potential collapse in animal tissue. Human trials confirm that melatonin improves mitochondrial respiratory chain complex function and lowers oxidative stress in neurodegenerative cohorts, though direct human cyanide challenge data are absent. Melatonin Matrix Profile, 2024 | Level B (Human Trial) / Level D (Preclinical) | Strong Support (Mitochondrial Guarding) / Plausible (COX Rescue) |
| Melatonin drops bulk and interfacial water viscosity to free water molecules for protein hydration shell stabilization. | Theoretical biophysical fluid dynamic frameworks and commentaries. | Melatonin modifies redox-driven water dynamics indirectly via ROS clearance, but direct physical manipulation of interfacial water viscosity to govern phase state remains an unproven theoretical model in human biology. Loh & Reiter, 2022 | Level D (Translational Gap) | Speculative |
IV. Actionable Protocol (Prioritized)
High Confidence Tier (Level A/B Evidence)
- Mitochondrial Bioenergetic Support: To enhance mitochondrial respiratory chain complex efficiency and suppress systemic lipid peroxidation in neurodegenerative or high-oxidative stress states, utilize verified clinical oral ranges (20 mg to 40 mg daily). This application is supported by double-blind randomized controlled trials showing restored mitochondrial complex activity and enhanced catalase markers.
- Standard Circadian Resynchronization: Restrict sleep onset interventions to standard low-dose ranges (0.3 mg to 5.0 mg), administered 30 to 60 minutes prior to nocturnal rest, to prevent receptor saturation while securing core chronobiotic alignment.
Experimental Tier (Level C/D Evidence)
- Preclinical Biomarkers Scale-Down: In translating animal mitochondrial rescue protocols (such as the 10 mg/kg IP rodent dose used to counteract ruthenium red toxicity), utilize strict allometric interspecies scaling equations. This ensures human equivalent doses remain within calculated, safety-monitored ceilings, while explicitly acknowledging that human in vivo phase-separation modification remains unproven.
- Epitranscriptomic and Membrane Fluidity Optimization: Rely on standard physiological dosing to support lipid bilayer fluidity and suppress microglial NLRP3 inflammasome activation via mitochondrial membrane potential preservation.
5 Likes
Wow, it looks like I should buy a bag of melatonin just in case. Crazy high dosage. I take 36 every night and thought that was a lot.
1 Like
My health protocol is so extensive that it is hard to be sure of exact changes. I can say it increased my energy and made my periods more regular.
3 Likes
Repairing DNA Damage: Scientists Identify New Benefits of Melatonin Supplementation
Researchers say that larger studies examining varying doses and long-term effects are now warranted.
A small clinical trial, published in Occupational & Environmental Medicine, suggests that melatonin supplementation may help counteract DNA damage linked to night shift work by enhancing the body’s ability to repair it.
The researchers emphasize the need for larger studies to explore different dosages and assess the potential long-term effects of melatonin supplementation.
Night shift workers experience suppressed nighttime production of melatonin, a key hormone regulating the body’s internal clock. This suppression weakens the body’s ability to repair oxidative DNA damage—a natural byproduct of cellular processes—potentially increasing the risk of certain cancers.
To investigate whether melatonin supplementation could mitigate this damage by improving DNA repair, the researchers conducted a study involving 40 night shift workers.
5 Likes
Once this is properly researched and sufficient priority is given to brain cell protection rather than minimising the exposure of other cells to melatonin I will be surprised if the recommended dosage is under 100mg per night.
Getting to this point, however, may take 10-30 years as there is no money to be made here and Trump’s team have decided to shut down a lot of US research. (regardless as to what is being researched).
I have, however, cited the papers with measurements of CSF melatonin levels which are the levels that anyone who wishes to protect their brain cells should be aware of.
5 Likes
In a 1-month randomised placebo-controlled trial, we demonstrated that consumption of a 3 mg melatonin supplement before engaging in daytime sleep improved the ability of night shift workers to repair oxidative DNA damage. No previous trials of melatonin supplementation and oxidative DNA damage have been conducted.
A dose of 3 mg of melatonin was selected for the study because it would likely produce physiological to supraphysiological levels of circulating melatonin in most people even after accounting for interindividual variation in bioavailability of melatonin.
Large interindividual variation in bioavailability of exogenous melatonin poses a challenge to identifying ideal doses of melatonin supplements for intervention/treatment.
In addition, previous research has demonstrated that even high doses of melatonin do not tend to produce sedative effects.
Given the limited scope of the trial, we were unable to evaluate multiple doses of melatonin supplements, nor were we able to evaluate the long-term efficacy of melatonin supplementation.
Our randomised placebo-controlled trial suggested melatonin supplementation may improve oxidative DNA damage repair capacity among night shift workers. Our findings warrant larger-scale trials considering multiple doses of melatonin, interindividual variability in melatonin bioavailability, and the impacts of long-term use of supplements. Assessing long-term efficacy is critical since those who work night shifts for many years would need to consistently consume melatonin supplements over that time frame to maximise the potential cancer prevention benefits.
Melatonin also extends lifespan in animal models: Melatonin and its possible anti-ageing properties
Not tested in the ITP though.
4 Likes
@John_Hemming: is there an easy way to measure creatinine-adjusted 8-hydroxy-2′-deoxyguanosine (8-OH-dG)?
The Exposure Biology and Analytical Chemistry Laboratory at Duke University used high pressure liquid chromatography-tandem mass spectrometry to measure 8-OH-dG and 6-sulfatoxymelatonin (aMT6s), a marker of circulating melatonin levels, in each urine sample.18 19 A second set of urine samples from a randomly selected 10% of participants were dispersed among study samples as blind duplicates. Values below the limit of detection (LOD) were replaced with LOD/√2.20 Creatinine was measured in the urine samples with the Creatinine Colorimetric Assay Kit (Cayman Chemical) and a microplate reader. Concentrations of 8-OH-dG and aMT6s were creatinine adjusted for all analyses and expressed as ng/mg-creatinine concentrations.
This would allow us to see the benefits of various doses from 1 mg to 1,000 mg.
Interesting ongoing trials:
- Disease Modifying Potential of 5mg of Melatonin on Cognition and Brain Health in Aging (NCT03954899): “The study will examine whether 5mg melatonin (over the counter, OTC) over a 9-month period improves Alzheimer’s disease (AD) biomarkers and cognitive function in two groups of individuals: those with mild cognitive impairment (MCI+) and those who are not (MCI-).” Results in 2026
- Effects of 3-Month Melatonin Treatment on Regional Cerebellar Structure and Blood Biomarkers in Alzheimer’s Disease Spectrum (NCT06756828): 2 mg, results in 2027.
- Oral Bedtime Melatonin in Critically Ill Patients (Mel-ICU) (NCT06156059): 100 mg daily, results in 2027.
1 Like
The problem testing endogenous metabolites is that unless the concentration shifts by a material amount the outcomes wont shift by a material amount.
1 Like
And yet the 3 mg study found significant improvement in DNA damage! (But in a particular population that might have low baseline levels)
2 Likes
True. In the end each molecule of ROS can only be reduced once (as a rule). Melatonin starts with the ability to reduce 9-10 molecules of ROS. If there is not enough melatonin for all the ROS then additional melatonin helps. There question in the end is how much damage the ROS does because it is not caught by melatonin.
At a point, however, adding melatonin will not do that much.
2 Likes
Several urine tests available on Rupa test this. DUTCH and GDX Metabolomix+ to name two. It’s interesting that night shift workers have elevated 8-OH-dG. Personally I have elevated F2-isoprostane (another marker of oxidative stress) but my 8-OH-dG is normal.
1 Like
Strange, they state that 8-OH-dG increases with melatonin supplementation. AIUI, we want 8-OH-dG to be low as it is an indication of oxidative stress damaging DNA. What am I missing here?
1 Like
What time do you think it’s best to take the higher doses?
1 Like
The night shift workers with a certain Melatonin MT2 receptor mutation are especially prone to night-shift related problems and increased risk of Alzheimer’s disease.
The same mutation increases risk of dementia in people older than 85 yo.
Both groups have a lower baseline melatonin levels.
I tried to find any information about using higher doses of Melatonin for prevention of dementia in this population, but unsuccessfully.
3 Likes
If I take a sub-milligram dose, I feel hung over the next day. If I took a massive dose, the hangover could be equally as massive.
1 Like
Per ChatGPT (I have no idea whether this is correct or not):
In most contexts, a high level of 8-OH-dG in tissue might indicate that there’s significant oxidative damage. However, when we measure urinary 8-OH-dG, we’re actually capturing a by‐product of the DNA repair process. When DNA damage occurs, cells use repair mechanisms—specifically, the base excision repair pathway—to excise damaged bases like 8-OH-dG from the DNA. Once excised, these modified bases are excreted in the urine.
Increased urinary 8-OH-dG excretion during daytime sleep (with melatonin) suggests that the repair process is more active. Melatonin appears to boost the repair machinery, leading to the removal and subsequent excretion of more oxidized bases.
Conversely, if repair were impaired, the damaged bases might remain in the DNA rather than being excreted, resulting in lower urinary levels even though the cellular damage is higher.
Thus, while you might intuitively think “less 8-OH-dG is better” because it signifies less damage, in this study, higher urinary 8-OH-dG actually indicates that the body is effectively repairing and clearing oxidative damage. Essentially, the assay is using 8-OH-dG excretion as a surrogate for repair capacity rather than a direct measure of oxidative stress burden.
1 Like